Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Acute kidney injury in 2013

Breaking barriers for biomarkers in AKI—progress at last

Nature Reviews Nephrology volume 10, pages 74–76 (2014)Cite this article

Subjects

In 2013, four important papers were published that provide new insights on biomarkers in acute kidney injury (AKI). These studies demonstrate the potential for biomarkers to aid clinicians in improving the therapeutic management of patients with AKI and potentially improve patient outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Proposed utilization of biomarkers in AKI.

References

  1. Mehta, R. L. Acute kidney injury: urine output in AKI—the canary in the coal mine? Nat. Rev. Nephrol. 9, 568–570 (2013).

    Article  CAS  PubMed  Google Scholar 

  2. Mandelbaum, T. et al. Empirical relationships among oliguria, creatinine, mortality, and renal replacement therapy in the critically ill. Intensive Care Med. 39, 414–419 (2013).

    Article  CAS  PubMed  Google Scholar 

  3. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int. Suppl. 2, 8–12 (2012).

  4. Murray, P. T. et al. Current use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. http://dx.doi.org/10.1038/ki.2013.374.

  5. Nickolas, T. L. et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59, 246–255 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kashani, K. et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16, 535–543 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Goldstein, S. L. & Chawla, L. S. Renal angina. Clin. J. Am. Soc. Nephrol. 5, 943–949 (2010).

    Article  PubMed  Google Scholar 

  9. Basu, R. K. et al. Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children. Kidney Int. http://dx.doi.org/10.1038/ki.2013.349.

  10. Cruz, D. N. et al. Renal angina syndrome and risk of severe acute kidney injury in critically ill patients. Clin. J. Am. Soc. Nephrol. (in press).

Download references

Author information

Authors and Affiliations

  1. University of California, San Diego Medicine 8342, UCSD Medical Center, 200 West Arbor Drive, San Diego, 92103, CA, USA

    Dinna N. Cruz & Ravindra L. Mehta

Authors
  1. Dinna N. Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravindra L. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravindra L. Mehta.

Ethics declarations

Competing interests

R. L. Mehta and D. N. Cruz participated in the Acute Dialysis Quality Initiative consensus conference and contributed to drafting the consensus recommendations. D. N. Cruz has received speaking honoraria from Alere and Toray. R. L. Mehta works on clinical research studies with Allocure, Cytopherx, Eli Lilly and Thrasos Therapeutics. He is a consultant for AbbVie, Baxter, CSL Behring, Gambro, GlaxoSmithKline and Grifols. He is an advisor to Astute, the sponsor for the Sapphire study.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cruz, D., Mehta, R. Breaking barriers for biomarkers in AKI—progress at last. Nat Rev Nephrol 10, 74–76 (2014). https://doi.org/10.1038/nrneph.2013.268

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2013.268

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research